The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -2,947 |
| Share based compensation | 665 |
| Loss on common stock warrant liabilities | 0 |
| Change in fair value of warrant liability | -15 |
| Issuance of stock under founders agreement | 76 |
| Common stock, issued to fortress, value | 55 |
| License expenses paid in kind | 0 |
| Gain on repurchase of common stock held by annji | 4 |
| Issuance of common stock of subsidiary | 37 |
| Prepaid expenses and other current assets | -2 |
| Accounts payable and accrued expenses-Nonrelated Party | -186 |
| Accounts payable and accrued expenses-Related Party | 484 |
| Net cash and cash equivalents used in operating activities | -1,833 |
| Proceeds from atm sales of common stock, net of issuance costs | 2,094 |
| Proceeds from exercise of warrants | 0 |
| Warrant exercise transaction costs | 0 |
| Net cash provided by financing activities | 2,094 |
| Net change in cash and cash equivalents | 261 |
| Cash and cash equivalents, beginning of period | 2,594 |
| Cash and cash equivalents, end of period | 2,855 |
AVENUE THERAPEUTICS, INC. (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI)